دورية أكاديمية

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.

التفاصيل البيبلوغرافية
العنوان: Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
المؤلفون: Spira, Alexander, Wertheim, Michael S, Kim, Edward J, Tan, Benjamin, Lenz, Heinz-Josef, Nikolinakos, Petros, Rich, Patricia L, Jehl, Genevieve, Machl, Andreas, Ito, Rena, Gulley, James L, Kopetz, Scott
المصدر: Oncologist; Feb2023, Vol. 28 Issue 2, pe124-e127, 4p, 1 Chart, 1 Graph
مصطلحات موضوعية: TRANSFORMING growth factors-beta, PROGRAMMED death-ligand 1, CLINICAL trials, TREATMENT duration, COLORECTAL cancer, CANCER patients, TREATMENT effectiveness, RESEARCH funding, DESCRIPTIVE statistics, RECOMBINANT proteins, PATIENT safety
مستخلص: Colorectal cancer (CRC) is a heterogeneous and complex disease with limited treatment options. Targeting transforming growth factor β (TGF-β) and programmed death ligand 1 pathways may enhance antitumor efficacy. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-β receptor II (a TGF-β "trap") fused to a human IgG1 monoclonal antibody blocking programmed cell death ligand 1. We report results from an expansion cohort of a phase I study (NCT02517398) in patients with heavily pretreated advanced CRC treated with bintrafusp alfa. As of May 15, 2020, 32 patients with advanced CRC had received bintrafusp alfa for a median duration of 7.1 weeks. The objective response rate was 3.1% and the disease control rate was 6.3% (1 partial response, 1 stable disease); 2 patients were not evaluable. The safety profile was consistent with previously reported data. A phase I study of bintrafusp alfa showed early signs of clinical efficacy and a manageable safety profile in patients with heavily pretreated solid tumors. [ABSTRACT FROM AUTHOR]
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:10837159
DOI:10.1093/oncolo/oyac254